For research use only. Not for therapeutic Use.
OXFBD04 is a potent and selective BRD4 inhibitor with an IC50 of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity[1].
OXFBD04 (0.01-100 μM; 48 hours) inhibits cancer cell lines growth[1].
OXFBD04 (10 µM; for 10, 24, or 48 hours) induces MYC suppression in MCF7 breast cancer cells[1].
OXFBD04 has optimised physicochemical properties (LE=0.43; LLE=5.74; SFI=5.96), and good metabolic stability (t1/2=388 min). OXFBD04 has CLint of 3.57 µL/min/mg[1].
| Catalog Number | I017336 |
| CAS Number | 2231747-03-6 |
| Synonyms | 3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-[hydroxy(pyridin-3-yl)methyl]phenol |
| Molecular Formula | C17H16N2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H16N2O3/c1-10-16(11(2)22-19-10)13-6-14(8-15(20)7-13)17(21)12-4-3-5-18-9-12/h3-9,17,20-21H,1-2H3 |
| InChIKey | RFDVEAHRRMEOHK-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=NO1)C)C2=CC(=CC(=C2)O)C(C3=CN=CC=C3)O |
| Reference | [1]. Jennings LE, et al. BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability. Bioorg Med Chem. 2018 Jul 15;26(11):2937-2957. |
